EDAP TMS reports 140% QoQ Focal One net placement growth, 76.8% YoY HIFU rev. growth.

Thursday, Aug 28, 2025 7:04 am ET1min read

• Focal One net placement grows 140% YoY. • HIFU revenue increases 76.8% YoY. • 36 million Euro credit facility with EIB to accelerate HIFU growth. • 2025 HIFU revenue growth guidance raised to 26%-34%. • Company to host conference call today at 8:30 a.m. EDT.

EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, has secured a €36 million credit facility from the European Investment Bank (EIB) to support the expansion of its Focal One® Robotic HIFU technology for early-stage prostate cancer treatment and accelerate the development of new clinical indications. The credit facility, expected to close by the end of 2025, will provide low-interest funding accessible in tranches, enhancing EDAP's balance sheet and supporting its growth strategy.

The announcement follows a strong financial performance, with Focal One net placement growing 140% year-over-year (YoY) and HIFU revenue increasing by 76.8% YoY. The company has also raised its 2025 HIFU revenue growth guidance to a range of 26% to 34%.

CEO Ryan Rhodes highlighted the strategic significance of the financing, stating, "The capital raised through this financing immediately enhances our balance sheet, offering a substantial source of low-interest funding that we can access in tranches as needed. Over the last several years, the EIB has been an extraordinary partner in helping companies deliver new and promising innovative technologies for the benefit of millions of patients across the globe. I would like to thank the EIB for their support, as we believe this additional capital will enable more physicians and their patients to access the benefits of Focal One Robotic HIFU."

EDAP TMS SA is recognized for its innovation in robotic energy-based therapies, combining ultrasound technology with advanced imaging and robotics to develop minimally invasive medical devices. The company's Focal One® system is designed to treat early-stage prostate cancer, with potential for expansion into multiple indications.

The company will host a conference call today at 8:30 a.m. EDT to discuss the credit facility and other financial developments.

References:
[1] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html

Comments



Add a public comment...
No comments

No comments yet